Type 1 vs Type 2 Diabetes: 8 Differences Most People Get Wrong

I have lost count of how many times I have heard someone say "type 1 is the kids' kind and type 2 is the kind you get from eating too much sugar." It sounds tidy. It is also wrong in at least three ways.

When our team started researching this piece, we expected to write a simple comparison. Instead, we found that some of the most common beliefs about type 1 diabetes (T1D) and type 2 diabetes (T2D) have been overturned by research published in just the last few years. Adults get type 1 more often than children do. Teenagers now develop type 2 at alarming rates. And one type can go into remission while the other can, for the first time, be delayed with a drug.

The stakes are high. According to the CDC's National Diabetes Statistics Report, an estimated 40.1 million people in the U.S. had diagnosed or undiagnosed diabetes in 2023, or 12.0% of the population, and about 11.0 million adults have it without knowing. Globally, the IDF Diabetes Atlas reports that 589 million adults aged 20 to 79 live with diabetes, and 252 million of them (43%) are undiagnosed. Diabetes caused 3.4 million deaths in 2024, roughly one every 9 seconds.

If we are going to talk about a condition this common, we should at least get the basics right. Below are the 8 differences we see people misunderstand most often, backed by data, expert quotes, and the clinical terms your doctor might actually use.

Type 1 vs Type 2 at a Glance

Before we get into the myths, here is the side-by-side view we wish someone had handed us years ago.

Feature	Type 1 Diabetes	Type 2 Diabetes
Core mechanism	Autoimmune destruction of pancreatic beta cells, leading to absolute insulin deficiency	Insulin resistance plus progressive beta-cell dysfunction
Share of U.S. adult cases	About 5% to 10%	About 90% to 95%
U.S. prevalence	~2.1 million people diagnosed	~27 million diagnosed
Typical onset	Often rapid, days to weeks	Often gradual, over years
Key lab markers	Islet autoantibodies (such as GAD65), low C-peptide	Normal or high C-peptide early, no autoantibodies
Insulin required?	Always	Sometimes, often later in the disease
Can it go into remission?	No, but onset can now be delayed	Yes, in many cases, through major weight loss
Family link	Weaker than most people think	Stronger than most people think

Sources: CDC, PubMed / BMJ 2018, American Diabetes Association

1. Type 1 Is Not a "Childhood" Disease. Most New Cases Are in Adults.

This is the misconception that surprised me the most. Type 1 diabetes was called "juvenile diabetes" for decades, and the name stuck in the public imagination.

The data tell a different story. A 2026 study in The Lancet Diabetes & Endocrinology notes that recent epidemiological evidence shows more than half of all clinical type 1 diagnoses happen in adulthood. CDC figures back this up: of the 2.1 million Americans with diagnosed type 1, 1.8 million are adults aged 20 or older, compared with 314,000 children and adolescents.

The real problem is what happens next. Because doctors (and patients) associate type 1 with kids, adults who develop it are frequently told they have type 2. An editorial in The Lancet Regional Health: Europe estimates that up to 40% of adults over 30 with type 1 diabetes may have been misdiagnosed with type 2.

Why this matters in practice: An adult misdiagnosed with type 2 might be started on oral drugs like metformin, which cannot replace the insulin their immune system is destroying. Their blood glucose keeps climbing, and some end up in the emergency room with diabetic ketoacidosis (DKA). If you are an adult with new diabetes, a normal BMI, and rapid weight loss, it is reasonable to ask about an autoantibody panel and a C-peptide test. You may also hear the term LADA (latent autoimmune diabetes in adults), which describes a slower-progressing form of autoimmune diabetes in grown-ups.

2. Weight Does Not Tell You Which Type Someone Has

We have all seen the stereotype: type 1 means thin, type 2 means overweight. We found that this one has quietly fallen apart.

A nationally representative analysis from the Johns Hopkins Bloomberg School of Public Health, published in Annals of Internal Medicine, found:

62% of U.S. adults with type 1 diabetes have overweight or obesity
64% of adults without diabetes have overweight or obesity
86% of adults with type 2 diabetes have overweight or obesity

In other words, people with type 1 carry excess weight at nearly the same rate as the general public. Senior investigator Elizabeth Selvin, PhD, said the findings bust "the myth that people with type 1 diabetes are not being affected" by the obesity epidemic.

Researchers now even use the term "double diabetes" to describe people with type 1 who also develop the insulin resistance typical of type 2. The reverse holds too: plenty of people with type 2 have a normal BMI, especially in South Asian and East Asian populations where metabolic risk appears at lower body weights.

The takeaway I keep coming back to: Body size is a risk factor, not a diagnostic test. The only reliable way to tell the types apart is with lab work.

3. Type 2 Runs in Families More Strongly Than Type 1

Most people assume that type 1, being "genetic," is the one that runs in families. The research points the other way.

The American Diabetes Association explains that type 2 has a stronger link to family history than type 1. Their identical twin data is the clearest illustration we found:

When one identical twin has type 1, the other develops it at most half the time
When one identical twin has type 2, the other's risk is up to 3 in 4

A review in PMC on the genetics of type 2 diabetes adds that lifetime risk is around 40% with one affected parent and 70% if both parents have it. Heritability estimates for T2D range from about 25% to as high as 72% depending on the study, according to the NIH's Diabetes in America.

Type 1 does have a genetic basis, concentrated in immune-system genes called HLA-DR and HLA-DQ, as noted in a Lancet seminar on type 1 diabetes. But here is the twist: most people diagnosed with type 1 have no close relative with it. Type 2, by contrast, is polygenic, meaning hundreds of small genetic variants each nudge risk up a little, and shared family habits (diet, activity, sleep) compound that risk.

What we tell friends: If your parent has type 2, that is a genuine signal to get an HbA1c test. If your parent has type 1, your own type 2 risk is not meaningfully affected.

4. Kids Are Now Getting Type 2, and the Trend Is Accelerating

If type 1 is not just for kids, type 2 is no longer just for older adults.

The U.S. SEARCH for Diabetes in Youth study has tracked new cases since 2002. According to a 2025 review in Diabetes Care, youth-onset type 2 incidence rose from 9.0 cases per 100,000 per year in 2002 to 2003 to 17.9 in 2017 to 2018, an average annual increase of 5.3%. The steepest climbs were among Asian/Pacific Islander (8.92% per year), Hispanic (7.17%), and non-Hispanic Black (5.99%) youth.

One data point genuinely stopped me. Among teens aged 15 to 19, the NIH's Endotext reports that type 2 incidence (19.7 per 100,000) overtook type 1 incidence (14.6 per 100,000) for the first time in 2017 to 2018.

Looking ahead, CDC projections suggest that if current trends continue, type 2 cases among young people could rise by about 700% by 2060. Puberty itself increases insulin resistance, which is why most youth cases appear in the teen years rather than early childhood.

5. Sugar Does Not Cause Type 1, and Type 2 Is More Than "Eating Too Much"

I understand why people link diabetes with sugar. Blood sugar is the thing being measured, after all. But the cause is different for each type.

Type 1 is an autoimmune disease. The body's own T cells attack insulin-producing beta cells in the pancreatic islets. Nothing a person ate triggered it, and no diet could have prevented it. The process often starts years before symptoms, marked by the appearance of islet autoantibodies in the blood.

Type 2 is more complex than "too much sugar." Professor Roy Taylor of Newcastle University and colleagues describe it, in a review in The Lancet Diabetes & Endocrinology, as largely driven by excess fat accumulating inside the liver and pancreas. Fat in the liver increases hepatic glucose production, and fat in the pancreas stresses the beta cells until they stop secreting insulin properly. Taylor calls this the "twin cycle" hypothesis.

Genetics, age, sleep, stress, certain medications, and ethnicity all shape who crosses that threshold. That is why two people with the same diet can have very different outcomes, and why blaming people with type 2 for their diagnosis misses the science.

6. Type 2 Can Go Into Remission, and Type 1 Can Now Be Delayed

For a long time, both types were described as permanent and progressive. That framing is now outdated for both.

Type 2 remission is real

The landmark DiRECT trial in the UK tested a structured, low-calorie weight management program delivered in ordinary GP practices. According to Diabetes UK:

46% of participants were in remission at 1 year
36% were in remission at 2 years
At 5 years, diaTribe reports that 23% of participants stayed in remission

Remission here means an HbA1c below 6.5% without any glucose-lowering medication. Among participants who kept off more than 10 kg at two years, 81% were in remission. Taylor summarized the five-year findings by saying long-term remission "is possible if sufficient weight loss is achieved" and maintained.

Type 1 cannot be reversed, but it can be delayed

In November 2022, the FDA approved teplizumab (Tzield), an anti-CD3 monoclonal antibody and the first disease-modifying therapy for type 1. In the pivotal trial, median time to clinical (stage 3) type 1 was 50 months with teplizumab versus 25 months with placebo, a delay of roughly two years.

2026 has been a big year for this drug. In April, the FDA expanded the indication down to children as young as 1. Dr. Kimber Simmons of the Barbara Davis Center noted that young children are "often at the highest risk of progressing quickly and without warning." Then in June, the FDA granted accelerated approval for kids aged 8 to 17 who were recently diagnosed with stage 3 type 1, to slow the decline of their own insulin production. As Yale's Dr. Kevan Herold put it, "This drug helps preserve someone's ability to make their own insulin."

The catch is that you have to catch type 1 early, in stage 1 or stage 2, when autoantibodies are present but symptoms are not. That is why autoantibody screening programs, like the ones run by Type 1 Diabetes TrialNet, matter so much.

7. Taking Insulin Does Not Mean You Have Type 1

We hear this one constantly: "My uncle takes insulin, so he must have type 1." Not necessarily.

Here is the key distinction:

In type 1, insulin is life-sustaining from diagnosis. Without it, the body starts burning fat for fuel uncontrollably, producing ketones and eventually DKA.
In type 2, many people eventually need insulin because beta-cell function declines over time. Starting insulin is a treatment decision, not a change in diagnosis.

Doctors distinguish the types using lab tests rather than treatment history. The two most useful are:

Islet autoantibody tests (GAD65, IA-2, ZnT8, insulin autoantibodies). Positive results point toward autoimmune diabetes.
C-peptide, a byproduct released when the pancreas makes insulin. Low C-peptide signals the body is producing little insulin of its own.

Onset speed is another clue. Type 1 often shows up over days or weeks with intense thirst, frequent urination, blurred vision, and unexplained weight loss. The FDA notes that people with stage 2 type 1 have a 75% risk of progressing to clinical diagnosis within four to five years. Type 2 usually develops so gradually that, as the CDC points out, more than 1 in 4 adults with diabetes do not know they have it.

8. Type 2 Is Not the "Mild" Version

This is the misconception I think does the most damage, because it makes people take type 2 less seriously.

Type 2 accounts for roughly 90% to 95% of diabetes cases, which means it drives the vast majority of diabetes-related heart attacks, strokes, kidney failure, amputations, and vision loss. The American Diabetes Association estimates the total cost of diagnosed diabetes in the U.S. hit $412.9 billion in 2022, including $306.6 billion in direct medical costs.

The youth data is even more sobering. According to a SEARCH study analysis, diabetes-related complications and all-cause mortality are more common in youth-onset type 2 than in youth-onset type 1. Young people with type 2 often develop kidney disease, retinopathy, and neuropathy faster than their peers with type 1.

Adult-onset type 1 is no walk in the park either. A large Swedish National Diabetes Register study of more than 10,000 people with adult-onset type 1 found a 71% higher risk of all-cause death (hazard ratio 1.71) compared with population controls.

Our honest view: Neither type is "the bad one." Both are serious, both are manageable, and both reward early diagnosis.

What We Want You to Remember

After spending weeks with this research, here is how I would sum up the real differences between type 1 and type 2 diabetes:

Type 1 is autoimmune; type 2 is metabolic. That is the root difference, and everything else follows from it.
Age and weight are poor predictors. Adults get type 1, teens get type 2, and body size overlaps heavily between the two.
Family history matters more for type 2. If a parent has it, get screened.
Lab tests settle the question. Autoantibodies and C-peptide are what distinguish the types, not how someone looks or which medication they take.
The treatment picture is changing fast. Type 2 remission through weight loss is well documented, and type 1 can now be delayed if caught early.

With 1 in 4 American adults with diabetes still undiagnosed, the single most useful thing any of us can do is simple: ask for an HbA1c test at your next checkup, and if the result is high, ask which type of diabetes you have and how your doctor knows.